Latest research on Erbitux

Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

Erbitux side effects

Similarly, compared to non-pretreated group, 56.9% decrease was observed when A431 tumors were pretreated with Erbitux. [source, 2016]
There were 22.5% and 44.9%, respectively, decrease when tumor cells pretreated with Erbitux. [source, 2016]
The Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer (EXTREME) Phase III trial showed significant increases in overall survival, progression-free survival, and response rate for the combination of cetuximab and platinum/5-fluorouralcil compared with platinum/5-fluorouracil alone [186,187,188,189]. [source, 2015]
Erbitux (ERB, cetuximab), a monoclonal therapeutic antibody, binds to the extracellular domain of epidermal growth factor receptor (EGFR) to prevent the activation and subsequent dimerization of the receptor, to decrease receptor activation and dimerization and result in inhibition of signal transduction and anti-proliferative effects. [source, 2015]
To this end, cancer cells that were identified to secrete increased levels of the aforementioned soluble factors were allowed to grow as either monocultures or were co-cultured with MRC5 fibroblasts or the corresponding TAFs for 5 days in the presence of inhibitory antibodies against EGFR (Erbitux), mAb cMet (monoclonal antibody cMet), mAb IL6, mAb IGF1R (R1507). [source, 2015]
The resistance of lung cancer cell line, H596, to Erbitux in co-culture with fibroblasts and a corresponding increase in cMet expression and activation compared to the mono-cultures (S5B Fig), indicate that these cells have become resistant to EGFR therapy and depend on HGF produced by co-cultured fibroblasts for survival in co-cultures (Fig 6B). [source, 2015]
The rate of Erbitux internalization was significantly increased by protein G hexamer (6 mer). [source, 2015]
Flow cytometry measurement indicated that intracellular accumulation of Erbitux was augmented as the valency of protein G polygons increased (Fig. 6b). [source, 2015]
As expected, Grb2 recruitment was significantly down-regulated in cells incubated with the small kinase inhibitors Canertinib, Erlotinib, Lapatinib, Gefitinib and the monoclonal antibody Erbitux (Figure 5): We found between 90% and almost complete inhibition of Grb2 contrast increase upon stimulation by 170 nM EGF. [source, 2014]
One common side effect of cetuximab (Erbitux) treatment is allergic reactions. [source, 2014]